Showing 721-730 of 797 results for "".
- AHS Celebrates Award Winners at 66th Annual Scientific Meetinghttps://practicalneurology.com/news/ahs-celebrates-annual-award-winners-at-66th-annual-scientific-meeting/2470502/Twenty-four individuals who have contributed to the field of headache and migraine were recognized by the American Headache Society (AHS) at the 66th Annual Scientific Meeting held in San Diego, CA. Awards were given in a variety of categories to acknowledge outstanding publications, researc
- Lifestyle Changes Improved Cognition, Function, Aβ Biomarkers in People with Early Alzheimer Disease According to RCThttps://practicalneurology.com/news/lifestyle-changes-improved-cognition-function-av-biomarkers-in-people-with-early-alzheimer-disease-according-to-rct/2470499/Lifestyle changes, including diet, exercise, stress management, and participation in support groups, were associated with improved cognition and function in people with mild cognitive impairment (MCI) or early dementia due to Alzheimer disease (AD). People who received usual care showed no improv
- Synapse-Generating Small Molecule for ALS Receives Nod from FDA for Clinical Trialhttps://practicalneurology.com/news/synapse-generating-small-molecule-for-als-receives-nod-from-fda-for-clinical-trial/2470486/The Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for SPG302 (Spinogenix, San Diego, CA) for evaluation as a potential treatment for people with amyotrophic lateral sclerosis (ALS) as a once-daily pill. The safety, tolerability, and pharmacokinetics
- Ingrezza Treatment Associated with Sustained Improvements in Patients with Tardive Dyskinesiahttps://practicalneurology.com/news/ingrezza-treatment-associated-with-sustained-improvements-in-patients-with-tardive-dyskinesia/2470477/Results of a post hoc analysis of the KINECT-4 study showed that the majority of participants with tardive dyskinesia (TD) who completed 48 weeks of once-daily Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) treatment experienced clinically meaningful and sustained TD improvements.
- FDA Grants Breakthrough Therapy Designation to Delpacibart Etedesiran for Myotonic Dystrophy Type 1https://practicalneurology.com/news/fda-grants-breakthrough-therapy-designation-to-delpacibart-etedesiran-for-myotonic-dystrophy-type-1/2470471/Delpacibart etedesiran (del-desiran/AOC 1001; Avidity Biosciences, San Diego, CA) has been granted Breakthrough Therapy designation by the Food and Drug Administration (FDA) as an investigational treatment for myotonic dystrophy type 1 (DM1). Delpacibart etedesiran was previously granted Orphan D
- FDA Approves Ingrezza Sprinkle Formulation for Tardive Dyskinesia or Chorea Associated with Huntington Diseasehttps://practicalneurology.com/news/fda-approves-ingrezza-sprinkle-formulation-for-tardive-dyskinesia-or-chorea-associated-with-huntington-disease/2470463/The Food and Drug Administration (FDA) has approved a new sprinkle formulation of Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) for patients with tardive dyskinesia (TD) or chorea associated with Huntington disease (HD). The oral granule capsules (available in 40 mg, 60 mg, and 80
- Long-Term Data from LILAC-2 Study of Daybue for Rett Syndrome Reportedhttps://practicalneurology.com/news/long-term-data-from-lilac-2-study-of-daybue-for-rett-syndrome-reported/2470362/People who used Daybue (trofinetide; Acadia Pharmaceuticals, San Diego, CA) on a long-term basis showed improvements in the core symptoms of Rett syndrome, according to results of the 104-week LILAC-2 (NCT04776746) open-label extension (OLE) study. The safety profile results found in this OLE stu
- FDA Grants Fast Track Designation to Autologous Investigational Cell Therapy for Parkinson Diseasehttps://practicalneurology.com/news/fda-grants-fast-track-designation-to-autologous-investigational-cell-therapy-for-parkinson-disease/2470319/ANPD001 (Aspen Neuroscience, San Diego, CA), a personalized, autologous investigational cell therapy product, has been granted Fast Track designation by the Food and Drug Administration (FDA) for investigation as a potential treatment for Parkinson disease (PD). ANPD001 is intended to replace los
- FDA Updates Nuplazid Label to Clarify Medication’s Indicationhttps://practicalneurology.com/news/fda-updates-nuplazid-label-to-clarify-medications-indication/2470299/The Food and Drug Administration (FDA) has updated the label for Nuplazid (pimavanserin; Acadia Pharmaceuticals, San Diego, CA) with revisions to the boxed warning and clinical studies sections for this atypical antipsychotic. The changes are intended to clarify that Nuplazid is used to treat peo
- New Drug Application Accepted for Oral Granule Sprinkle Formulation of Ingrezzahttps://practicalneurology.com/news/new-drug-application-accepted-for-oral-granule-sprinkle-formulation-of-ingrezza/2470295/The Food and Drug Administration (FDA) accepted the new drug application (NDA) for Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) oral granules. This is a new sprinkle formulation of the once-daily capsule version of Ingrezza, which was approved previously to treat tardive dyskines